The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAP-100: First-in-class antibody for CCR7+ hematological malignancies.
 
Carlos Cuesta
Employment - Immed
Research Funding - Catapult Therapeutics
Patents, Royalties, Other Intellectual Property - Hospital La Princesa
Travel, Accommodations, Expenses - Immed
 
Cecilia Munoz-Callega
Patents, Royalties, Other Intellectual Property - Hospital la Princesa
Travel, Accommodations, Expenses - IMMED
 
Javier Loscertales
Honoraria - Abbvie; Gilead Sciences; Janssen
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen
Expert Testimony - Janssen
 
Fernando Terron
Employment - Catapult Therapeutics
Leadership - Catapult Therapeutics
Stock and Other Ownership Interests - IMMED
Patents, Royalties, Other Intellectual Property - IMMED
Travel, Accommodations, Expenses - IMMED
 
Wim Mol
Employment - Catapult Therapeutics
Leadership - Catapult Therapeutics
Honoraria - catapult Therapeutics
Travel, Accommodations, Expenses - catapult Therapeutics